Deal Snapshot
SMITH AND NEPHEW EXPANDS IN REGENERATIVE MEDICINE MARKET WITH ACQUISITION OF OSIRIS THERAPEUTICS
Thursday 14 March 2019

UK-based medical technology business Smith and Nephew plc (LSE: SN) (NYSE: SNN) has agreed to acquire US-based regenerative medicine specialist Osiris Therapeutics, Inc. (NASDAQ: OSIR) for USD 19.00 per share in cash, representing a total equity value of approximately USD 660m, the company said.
Osiris products include skin, bone graft and articular cartilage substitutes. The company delivered revenue of USD 102m for the nine-months ended 30 September 2018, an 18.7% increase over the comparable period in 2017.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 14/03/2019
Target: Osiris Therapeutics, Inc
Country: USA
Deal Size: 660m (USD)
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing: Cash
Status: Agreed
Vendor:
Buyer: Smith and Nephew
Comment:


Options